Table 2.
PASI scores at apremilast initiation and months 3 and 6 (REF)
| REF (N = 89) | |||
|---|---|---|---|
| Apremilast initiation | Month 3 | Month 6 | |
| PASI | |||
| n | 83 | 69 | 62 |
| Mean (SD) | 13.6 (6.8) | 6.4 (6.5) | 6.8 (7.3) |
| 95% CI | 12.1–15.0 | 4.8–8.0 | 5.0–8.7 |
| Change from baseline | |||
| n | NA | 64 | 57 |
| Mean (SD) | − 7.1 (6.0) | − 7.1 (6.4) | |
| Patients achieving PASI ≤ 3 | |||
| n | 83 | 69 | 62 |
| No, n (%) | 82 (98.8) | 45 (65.2) | 39 (62.9) |
| Yes, n (%) | 1 (1.2) | 24 (34.8) | 23 (37.1) |
| Patients achieving PASI 50 | |||
| n | 64 | 57 | |
| No, n (%) | NA | 18 (28.1) | 18 (31.6) |
| Yes, n (%) | 46 (71.9) | 39 (68.4) | |
| Patients achieving PASI 75 | |||
| n | 64 | 57 | |
| No, n (%) | NA | 45 (70.3) | 37 (64.9) |
| Yes, n (%) | 19 (29.7) | 20 (35.1) | |
n number of patients with available data or number of patients in the relevant category, PASI 50 reduction in PASI score of at least 50%, PASI 75 reduction in PASI score of at least 75%, CI confidence interval, NA not applicable, PASI Psoriasis Area and Severity Index, REF reference analysis set, SD standard deviation